Free Trial

ImmunoCellular Therapeutics (IMUCD) News Today

$0.17 +0.07 (+70.00%)
(As of 11/22/2024 ET)
RVVTF - Revive Therapeutics Ltd.
Get ImmunoCellular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMUCD and its competitors with MarketBeat's FREE daily newsletter.

917 Trades… Zero Losses? (Ad)

As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”

Go here to see how you can start accessing these opportunities today

IMUCD Media Mentions By Week

IMUCD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IMUCD
News Sentiment

0.00

0.49

Average
Medical
News Sentiment

IMUCD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IMUCD Articles
This Week

0

0

IMUCD Articles
Average Week

Get ImmunoCellular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMUCD and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (OTCMKTS:IMUCD) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners